| Literature DB >> 26920549 |
June Utnes Høgli1, Beate Hennie Garcia2, Frode Skjold3, Vegard Skogen4,5, Lars Småbrekke6.
Abstract
BACKGROUND: Appropriate antibiotic prescribing is associated with favourable levels of antimicrobial resistance (AMR) and clinical outcomes. Most intervention studies on antibiotic prescribing originate from settings with high level of AMR. In a Norwegian hospital setting with low level of AMR, the literature on interventions for promoting guideline-recommended antibiotic prescribing in hospital is scarce and requested. Preliminary studies have shown improvement potentials regarding antibiotic prescribing according to guidelines. We aimed to promote appropriate antibiotic prescribing in patients with community-acquired pneumonia (CAP) and acute exacerbations of chronic obstructive pulmonary disease (AECOPD) at a respiratory medicine department in a Norwegian University hospital. Our specific objectives were to increase prescribing of appropriate empirical antibiotics, reduce high-dose benzylpenicillin and reduce total treatment duration.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26920549 PMCID: PMC4769530 DOI: 10.1186/s12879-016-1426-1
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Fig. 1Overview of the three-phase audit and feedback intervention study
An abbreviated overview of the Norwegian clinical practice-guideline recommendations
| Infection | Drug | Dose | Duration |
|---|---|---|---|
| AECOPD | Benzylpenicillin (intravenous) | 1.2 g x 4 | 5 days |
| CAP | Benzylpenicillin (intravenous) | 1.2 g x 4 | 5–7 days |
| CAP | Benzylpenicillin (intravenous) | 3 g x 4 | 7–10 days |
Valid for hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and community-acquired pneumonia (CAP)
CRB-65 Confusion, respiration, blood pressure and age > 65y. aIn analysis categorized as inappropriate, see discussion
Patient characteristics of patients included pre- and post-intervention
| Pre-intervention | Post-intervention |
| |||
|---|---|---|---|---|---|
| n | (%) | n | (%) | ||
| Study participants | 253 | 155 | |||
| Female | 126 | (49.8) | 75 | (48.4) | NS |
| Age, years | NS | ||||
| Mean (range) | 71.4 | (78) | 72.1 | (75) | |
| Median | 73.0 | 73.0 | |||
| Infection | |||||
| AECOPD | 104 | (41.4) | 45 | (29.0) | 0.014 |
| Community-acquired pneumonia | 149 | (58.9) | 110 | (71.0) | |
| Nursing home residents | 25 | (9.9) | 9 | (5.8) | NS |
| Penicillin allergy | 32 | (12.6) | 9 | (5.8) | 0.03 |
| Risk factors for non-common bacteria or resistant bacteria | |||||
| Malignity or immunocompromised | 36 | (14.2) | 24 | (15.5) | NS |
| Preceding hospitalization last 30d | 57 | (22.5) | 24 | (15.5) | NS |
| Microbiological diagnostics | |||||
| Blood culture | 172 | (68.0) | 125 | (80.6) | 0.005 |
| Nasopharynx and/or expectorate | 205 | (81.0) | 141 | (91.0) | 0.007 |
| Pneumococcal urinary antigen test | 149 | (58.9) | 92 | (59.4) | NS |
| Othera | 157 | (62.1) | 104 | (67.1) | NS |
| None | 16 | (6.3) | 5 | (3.2) | NS |
| Aetiology | |||||
|
| 30 | (11.9) | 16 | (10.3) | NS |
|
| 12 | (4.7) | 13 | (8.4) | NS |
| Other bacteria | 15 | (5.9) | 11 | (7.1) | NS |
| Influenza virus A or B | 24 | (9.6) | 18 | (11.6) | NS |
| Other respiratory viruses | 34 | (13.4) | 30 | (19.4) | NS |
| None identified | 159 | (62.8) | 89 | (57.4) | NS |
| CRB-65 score | NS | ||||
| 0 | 25 | (16.8) | 16 | (14.5) | |
| 1 | 57 | (38.3) | 42 | (38.2) | |
| 2 | 48 | (32.2) | 32 | (29.1) | |
| 3 | 7 | (4.7) | 11 | (10.0) | |
| 4 | 2 | (1.3) | 1 | (0.9) | |
| Missing data | 10 | (6.7) | 8 | (7.3) | |
| Clinical outcomes | |||||
| Length of stay, median (range) | 5.3 | (34) | 5.9 | (33) | NS |
| 30 day mortality | 18 | (7.1) | 14 | (9.0) | NS |
| 30 day readmission | 55 | (22.8) | 24 | (16.7) | NS |
AECOPD Acute exacerbation of chronic obstructive pulmonary disease, CRB-65 Confusion, respiration, blood pressure and age ≥ 65y, aHigh prevalence due to urinary samples are included. For more detailed information on microbiological diagnostics, see Additional files 2, 3 and 4
Comparison of empirical antibiotic prescribing pre- and post-intervention, expressed as percentage-point difference
| Antibiotic agent | Pre-intervention (%) | Post-intervention (%) | Percentage-point difference |
|---|---|---|---|
| Benzylpenicillina | 41.1 | 53.5 | +12.4 |
| Benzylpenicillin + gentamicina | 8.3 | 16.1 | +7.8 |
| Ampicillin and amoxicillina | 12.3 | 14.2 | +1.9 |
| Cephalosporinesb | 16.2 | 9.7 | −6.5 |
| Tetracyclinesb | 14.6 | 3.2 | −11.0 |
| Macrolides | 2.8 | - | −2.8 |
| Others | 4.7 | 3.2 | −1.9 |
Proportion of patients prescribed the specific antibiotics is calculated based on number of study participants pre- and post-intervention (n = 253 and 155, respectively)
aCategorized as appropriate, and targeted for increase, bFor cephalosporines and doxycyclines percentage difference was −3.8 % and −21.6 % in patients with acute exacerbation of chronic obstructive pulmonary disease and −11.2 % and −2.0 % in patients with community-acquired pneumonia, respectively
Fig. 2Trend and level change in monthly prescribing of appropriate empirical antibiotics, pre- and post-intervention. Appropriate antibiotics comprise benzylpenicillin in monotherapy, benzylpenicillin in combination with gentamicin, or amoxicillin/ampicillin. Pre-intervention audit started January 2014 (point no.1), the intervention was performed late September 2014 (point no. 9) and the post-intervention audit ended March 2015 (point no. 15)
Monthly prescribing of appropriate empirical antibiotics and total treatment duration, estimated with interrupted times series
| Appropriate empirical antibioticsa | Total treatment duration | |||||
|---|---|---|---|---|---|---|
| Percent |
| SE | Days |
| SE | |
| Intercept β0 | 68.3 | 5.3 | 11.5 | 0.4 | ||
| Trend before intervention β1 | −1.3 | ns | 0.9 | −0.07 | ns | 0.1 |
| Effect one month after intervention β2 | 14.1 | ns | 8.5 | −1.4 | 0.04 | 0.9 |
| Effect six month after intervention β2 | 45.4 | 0.002 | 11.0 | 0.57 | ns | 0.8 |
| Trend change after intervention β3 | 4.1 | 0.02 | 2.9 | 0.27 | 0.03 | 0.14 |
Trends pre- and post intervention, and effect of the intervention on prescribing one and six months after the intervention (level change) are reported
aComprise benzylpenicillin in monotherapy, benzylpenicillin in combination with gentamicin, or amoxicillin/ampicillin, ns; data is considered non-significant when P > 0.05, SE Standard error
Fig. 3Trend and level change in monthly mean total treatment duration, pre- and post-intervention. Total treatment duration was defined as in-hospital prescribing plus length of prescription at discharge. Pre-intervention audit started January 2014 (point no. 1), the intervention was performed late September 2014 (point no. 9) and the post-intervention audit ended March 2015 (point no. 15)